Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/05/17
End: 02/09/18
Due: 02/09/19
Phase: N/A
Priority: Normal
Start: 11/30/20
End: 06/30/23
Due: 06/30/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | NCT02982720 | Aiwu Ruth He, MD | user2@example.com | None | 2017-07-05 | 2018-02-09 | 2019-02-09 | - | - | 2025-07-14 |
| Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | NCT04541173 | Aiwu Ruth He, MD | user2@example.com | None | 2020-11-30 | 2023-06-30 | 2024-06-30 | - | - | 2025-07-14 |